Status:
COMPLETED
A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-we...
Eligibility Criteria
Inclusion
- Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.
Exclusion
- Subjects with clinically significant cardiovascular disease in the past 6 months.
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT00143286
Start Date
April 1 2003
End Date
March 1 2005
Last Update
June 4 2007
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Santa Ana, California, United States
2
Pfizer Investigational Site
West Palm Beach, Florida, United States
3
Pfizer Investigational Site
Lexington, Kentucky, United States
4
Pfizer Investigational Site
Mogadore, Ohio, United States